Notably, both HKDC1 and IGF2BP3 are essential for the regulation of glycolytic activity, and abnormally high expression of them has been reported in GC, which is consistent to current multidrug chemotherapies with a poor prognosis [25–27]. This evidence concerns the gene HKDC1 and gastric cancer.